1. Home
  2. TCI vs RIGL Comparison

TCI vs RIGL Comparison

Compare TCI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCI
  • RIGL
  • Stock Information
  • Founded
  • TCI 1983
  • RIGL 1996
  • Country
  • TCI United States
  • RIGL United States
  • Employees
  • TCI N/A
  • RIGL N/A
  • Industry
  • TCI Real Estate
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • TCI Finance
  • RIGL Health Care
  • Exchange
  • TCI Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • TCI 239.2M
  • RIGL 282.2M
  • IPO Year
  • TCI N/A
  • RIGL 2000
  • Fundamental
  • Price
  • TCI $28.20
  • RIGL $15.61
  • Analyst Decision
  • TCI
  • RIGL Buy
  • Analyst Count
  • TCI 0
  • RIGL 4
  • Target Price
  • TCI N/A
  • RIGL $31.13
  • AVG Volume (30 Days)
  • TCI 2.7K
  • RIGL 223.7K
  • Earning Date
  • TCI 11-07-2024
  • RIGL 11-05-2024
  • Dividend Yield
  • TCI N/A
  • RIGL N/A
  • EPS Growth
  • TCI N/A
  • RIGL N/A
  • EPS
  • TCI 0.69
  • RIGL N/A
  • Revenue
  • TCI $50,541,000.00
  • RIGL $130,201,000.00
  • Revenue This Year
  • TCI N/A
  • RIGL $38.26
  • Revenue Next Year
  • TCI N/A
  • RIGL $24.21
  • P/E Ratio
  • TCI $40.18
  • RIGL N/A
  • Revenue Growth
  • TCI N/A
  • RIGL 7.48
  • 52 Week Low
  • TCI $26.91
  • RIGL $7.10
  • 52 Week High
  • TCI $43.40
  • RIGL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • TCI 45.05
  • RIGL 60.01
  • Support Level
  • TCI $26.91
  • RIGL $15.22
  • Resistance Level
  • TCI $28.28
  • RIGL $16.85
  • Average True Range (ATR)
  • TCI 0.69
  • RIGL 0.86
  • MACD
  • TCI -0.01
  • RIGL -0.07
  • Stochastic Oscillator
  • TCI 45.37
  • RIGL 57.30

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: